

## ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary

### A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) *Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society*

#### WRITING COMMITTEE MEMBERS

Valentin Fuster, MD, PhD, FACC, FAHA, FESC, Co-Chair; Lars E. Rydén, MD, PhD, FACC, FESC, FAHA, Co-Chair; David S. Cannom, MD, FACC; Harry J. Crijns, MD, FACC, FESC\*; Anne B. Curtis, MD, FACC, FAHA; Kenneth A. Ellenbogen, MD, FACC†; Jonathan L. Halperin, MD, FACC, FAHA; Jean-Yves Le Heuzey, MD, FESC; G. Neal Kay, MD, FACC; James E. Lowe, MD, FACC; S. Bertil Olsson, MD, PhD, FESC; Eric N. Prystowsky, MD, FACC; Juan Luis Tamargo, MD, FESC; Samuel Wann, MD, FACC, FESC

#### ACC/AHA TASK FORCE MEMBERS

Sidney C. Smith, Jr, MD, FACC, FAHA, FESC, Chair; Alice K. Jacobs, MD, FACC, FAHA, Vice-Chair; Cynthia D. Adams, MSN, APRN-BC, FAHA; Jeffery L. Anderson, MD, FACC, FAHA; Elliott M. Antman, MD, FACC, FAHA‡; Jonathan L. Halperin, MD, FACC, FAHA; Sharon Ann Hunt, MD, FACC, FAHA; Rick Nishimura, MD, FACC, FAHA; Joseph P. Ornato, MD, FACC, FAHA; Richard L. Page, MD, FACC, FAHA; Barbara Riegel, DNSc, RN, FAHA

#### ESC COMMITTEE FOR PRACTICE GUIDELINES

Silvia G. Priori, MD, PhD, FESC, Chair; Jean-Jacques Blanc, MD, FESC, France; Andrzej Budaj, MD, FESC, Poland; A. John Camm, MD, FESC, FACC, FAHA, United Kingdom; Veronica Dean, France; Jaap W. Deckers, MD, FESC, The Netherlands; Catherine Despres, France; Kenneth Dickstein, MD, PhD, FESC, Norway; John Lekakis, MD, FESC, Greece; Keith McGregor, PhD, France; Marco Metra, MD, Italy; Joao Morais, MD, FESC, Portugal; Ady Osterspey, MD, Germany; Juan Luis Tamargo, MD, FESC, Spain; José Luis Zamorano, MD, FESC, Spain

\*European Heart Rhythm Association Official Representative.

†Heart Rhythm Society Official Representative.

‡Immediate Past Chair.

This document was approved by the American College of Cardiology Foundation Board of Trustees in June 2006; by the American Heart Association Science Advisory and Coordinating Committee in June 2006; and by the European Society of Cardiology Committee for Practice Guidelines in June 2006.

When this document is cited, the American College of Cardiology Foundation, the American Heart Association, and the European Society of Cardiology request that the following citation format be used: Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *J Am Coll Cardiol* 2006;48:854–906.

This article has been copublished in the August 15, 2006, issues of *Circulation* and the *Journal of the American College of Cardiology* and the August 16, 2006, issue of the *European Heart Journal*.

**Copies:** This document is available on the World Wide Web sites of the American College of Cardiology ([www.acc.org](http://www.acc.org)), the American Heart Association ([www.americanheart.org](http://www.americanheart.org)), and the European Society of Cardiology ([www.esccardio.org](http://www.esccardio.org)). Single and bulk reprints of both the online full-text guidelines and the published executive summary (published in the August 15, 2006, issues of *Circulation* and the *Journal of the American College of Cardiology* and the August 16, 2006, issue of the *European Heart Journal*) are available from Oxford University Press by contacting Special Sales ([special.sales@oxfordjournals.org](mailto:special.sales@oxfordjournals.org)), Journals Division, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Phone +44 (0) 1865 353827, Fax +44 (0) 1865 353774, Work Mobile +44 07841322925. Single copies of the executive summary and the full-text guidelines are also available by calling 800-253-4636 or writing the American College of Cardiology Foundation, Resource Center, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. To purchase bulk reprints, fax 212-633-3820 or e-mail [reprints@elsevier.com](mailto:reprints@elsevier.com). To purchase *Circulation* reprints: Up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4121, fax 410-528-4264, or e-mail [kelle.ramsay@wolterskluwer.com](mailto:kelle.ramsay@wolterskluwer.com).

**Permissions:** Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association or the European Society of Cardiology. Please direct requests to [copyright.permissions@heart.org](mailto:copyright.permissions@heart.org) or [journals.permissions@oxfordjournals.org](mailto:journals.permissions@oxfordjournals.org).

(*J Am Coll Cardiol* 2006;48:854–906.)

© 2006 by the American College of Cardiology Foundation, the American Heart Association, Inc, and the European Society of Cardiology.

## TABLE OF CONTENTS

Preamble.....	856
I. Introduction.....	856
A. Organization of Committee and Evidence Review.....	856
Classification of Recommendations.....	858
Level of Evidence.....	858
B. Changes Since the Initial Publication of These Guidelines in 2001.....	858
C. Recommendations for Management of Patients With Atrial Fibrillation.....	858
Recommendations.....	858
1. Pharmacological Rate Control During Atrial Fibrillation.....	858
2. Preventing Thromboembolism.....	859
3. Cardioversion of Atrial Fibrillation.....	860
a. Pharmacological Cardioversion.....	860
b. Direct-Current Cardioversion.....	861
c. Pharmacological Enhancement of Direct-Current Cardioversion.....	861
d. Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Cardioversion.....	861
4. Maintenance of Sinus Rhythm.....	862
5. Special Considerations.....	862
a. Postoperative Atrial Fibrillation.....	862
b. Acute Myocardial Infarction.....	863
c. Management of Atrial Fibrillation Associated With the Wolff-Parkinson-White (WPW) Preexcitation Syndrome.....	863
d. Hyperthyroidism.....	863
e. Management of Atrial Fibrillation During Pregnancy.....	863
f. Management of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy (HCM).....	864
g. Management of Atrial Fibrillation in Patients With Pulmonary Disease.....	864
II. Definition.....	864
A. Atrial Fibrillation.....	864
B. Related Arrhythmias.....	864
III. Classification.....	865
IV. Epidemiology and Prognosis.....	865
A. Prevalence.....	866
B. Incidence.....	866
C. Prognosis.....	866
V. Pathophysiological Mechanisms.....	866
A. Atrial Factors.....	866
1. Atrial Pathology as a Cause of Atrial Fibrillation.....	866
2. Mechanisms of Atrial Fibrillation.....	866
3. Atrial Electrical Remodeling.....	867
4. Other Factors Contributing to Atrial Fibrillation.....	867
B. Atrioventricular Conduction.....	867
1. General Aspects.....	867
2. Atrioventricular Conduction in Preexcitation Syndromes.....	868
C. Myocardial and Hemodynamic Consequences of Atrial Fibrillation.....	868
D. Thromboembolism.....	868
1. Pathophysiology of Thrombus Formation.....	868
2. Clinical Implications.....	869
VI. Causes, Associated Conditions, Clinical Manifestations, and Quality of Life.....	869
A. Causes and Associated Conditions.....	869
1. Reversible Causes of Atrial Fibrillation.....	869
2. Atrial Fibrillation Without Associated Heart Disease.....	869
3. Medical Conditions Associated With Atrial Fibrillation.....	869
4. Atrial Fibrillation With Associated Heart Disease.....	869
5. Familial Atrial Fibrillation.....	870
6. Autonomic Influences in Atrial Fibrillation.....	870
B. Clinical Manifestations.....	870
C. Quality of Life.....	870
VII. Clinical Evaluation.....	870
A. Basic Evaluation of the Patient With Atrial Fibrillation.....	870
1. Clinical History and Physical Examination.....	870
2. Investigations.....	870
VIII. Management.....	872
A. Strategic Objectives.....	872
B. Pharmacological and Nonpharmacological Treatment Options.....	872
1. Heart Rate Control Versus Rhythm Control.....	872
a. Pharmacological Rate Control During Atrial Fibrillation.....	874
b. Regulation of Atrioventricular Nodal Conduction by Pacing.....	874
c. Atrioventricular Nodal Ablation.....	874
2. Preventing Thromboembolism.....	876
a. Risk Stratification.....	876
b. Antithrombotic Strategies for Prevention of Ischemic Stroke and Systemic Embolism.....	877
c. Nonpharmacological Approaches to Prevention of Thromboembolism.....	879
3. Cardioversion of Atrial Fibrillation.....	880
a. Pharmacological Cardioversion.....	881
4. Pharmacological Agents to Maintain Sinus Rhythm.....	881
a. Agents With Proven Efficacy to Maintain Sinus Rhythm.....	881
b. Out-of-Hospital Initiation of Antiarrhythmic Drugs in Patients With Atrial Fibrillation.....	882
5. Direct-Current Cardioversion of Atrial Fibrillation and Atrial Flutter.....	885
a. Technical and Procedural Aspects.....	885
b. Risks and Complications of Direct-Current Cardioversion of Atrial Fibrillation.....	886
c. Pharmacological Enhancement of Direct-Current Cardioversion.....	886
d. Prevention of Thromboembolism in Patients With Atrial Fibrillation Undergoing Conversion.....	887
6. Maintenance of Sinus Rhythm.....	888
a. Pharmacological Therapy.....	888
b. Predictors of Recurrent Atrial Fibrillation.....	888
c. General Approach to Antiarrhythmic Drug Therapy.....	888
d. Selection of Antiarrhythmic Agents in Patients With Cardiac Diseases.....	889
7. Nonpharmacological Therapy for Atrial Fibrillation.....	889

Download English Version:

<https://daneshyari.com/en/article/2955400>

Download Persian Version:

<https://daneshyari.com/article/2955400>

[Daneshyari.com](https://daneshyari.com)